Download video

CHRYSALIS-2: MET IHC as a biomarker for amivantamab-lazertinib in NSCLC

35 views

VJOncology

1 month ago

CHRYSALIS-2: MET IHC as a biomarker for amivantamab-lazertinib in NSCLC

CHRYSALIS-2: MET IHC as a biomarker for amivantamab-lazertinib in NSCLC

CHRYSALIS-2: MET IHC as a biomarker for amivantamab-lazertinib in NSCLC
2:47
CHRYSALIS-2: MET IHC as a biomarker for amivantamab-lazertinib in NSCLC
by VJOncology
Managing Side Effects of New Treatments for Small Cell Lung Cancer
14:57
Managing Side Effects of New Treatments for Small Cell Lung Cancer
by OncBrothers: Practice-Changing Cancer Discussions
The Rapidly Changing Treatment Paradigm for Stage III Non-Small Cell Lung Cancer
54:10
The Rapidly Changing Treatment Paradigm for Stage III Non-Small Cell Lung Cancer
by ACCP CHEST
IMforte - Maintenance Lurbinectedin + Atezo FDA Approval for Extensive Small Cell Lung Cancer (SCLC)
25:31
IMforte - Maintenance Lurbinectedin + Atezo FDA Approval for Extensive Small Cell Lung Cancer (SCLC)
by OncBrothers: Practice-Changing Cancer Discussions
Navigating Treatment Choices for EGFRm NSCLC
1:37:01
Navigating Treatment Choices for EGFRm NSCLC
by Kavina Creations
How to treat Small Cell Lung Cancer in 2025
23:20
How to treat Small Cell Lung Cancer in 2025
by OncBrothers: Practice-Changing Cancer Discussions
What immunotherapy treatments are used for small cell lung cancer (SCLC)?
2:39
What immunotherapy treatments are used for small cell lung cancer (SCLC)?
by You and Lung Cancer
How to Treat Early Stage Non-Small Cell Lung Cancer in 2025
20:31
How to Treat Early Stage Non-Small Cell Lung Cancer in 2025
by OncBrothers: Practice-Changing Cancer Discussions